Amyotrophic Lateral Sclerosis Clinical Trials

11 trials recruiting in Canada.

Brain & Nervous System

Recruiting Drug Device Behavioral Older adults Healthy volunteers

11 trials

Testing Dazucorilant against a placebo for amyotrophic lateral sclerosis

Explore this study →

Sites in Hamilton and Montreal

RecruitingPHASE2

Official title: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis · Corcept Therapeutics

Comparing 6 approaches for amyotrophic lateral sclerosis (ALS)

Explore this study →

Sites in Edmonton, London and 2 more cities

RecruitingPHASE1

Official title: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Amyotrophic Lateral Sclerosis (ALS) · Regeneron Pharmaceuticals

Testing LY4256984 for amyotrophic lateral sclerosis

Explore this study →

Sites in London, Montreal and 1 more city

RecruitingPHASE1

Official title: A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis · Eli Lilly and Company

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for amyotrophic lateral sclerosis.

Testing Repetitive Transcranial Magnetic for amyotrophic lateral sclerosis

Explore this study →

One site, in Toronto

Recruiting

Official title: Quantitative and Repetitive TMS in ALS - Recruiting for Stage 2

Amyotrophic Lateral Sclerosis · Sunnybrook Health Sciences Centre

Testing 50 mg Usnoflast against a placebo for amyotrophic lateral sclerosis (ALS)

Explore this study →

Sites in Québec and Toronto

RecruitingPHASE2

Official title: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) · Zydus Therapeutics Inc.

Testing LY4256984 against a placebo for ALS (amyotrophic lateral sclerosis)

Explore this study →

Sites in Calgary, Edmonton and 3 more cities

RecruitingPHASE1

Official title: A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

ALS (Amyotrophic Lateral Sclerosis) · Eli Lilly and Company

Testing COYA 302 against a placebo for amyotrophic lateral sclerosis (ALS)

Explore this study →

Sites in London, Montreal and 2 more cities

RecruitingPHASE2

Official title: Study of COYA 302 for the Treatment of ALS

Amyotrophic Lateral Sclerosis (ALS) · Coya Therapeutics

Testing Pridopidine against a placebo for amyotrophic lateral sclerosis

Explore this study →

Sites in Edmonton, Hamilton and 1 more city

RecruitingPHASE3

Official title: Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Amyotrophic Lateral Sclerosis · Prilenia

Testing NB-4746 High dose against a placebo for amyotrophic lateral sclerosis (ALS)

Explore this study →

Sites in Fredericton and Montreal

RecruitingPHASE1

Official title: A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

Amyotrophic Lateral Sclerosis (ALS) · Nura Bio

Testing LY4256984 for amyotrophic lateral sclerosis

Explore this study →

Sites in London, Montreal and 1 more city

RecruitingPHASE1

Official title: A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis · Eli Lilly and Company

Testing Darifenacin against a placebo for amyotrophic lateral sclerosis

Explore this study →

Sites in Montreal and Ottawa

RecruitingPHASE2

Official title: A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Amyotrophic Lateral Sclerosis · Oliver Blanchard

Looking for the closest fit?

Get matched →

Get notified when a matching trial opens

We'll watch for Amyotrophic Lateral Sclerosis trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.